Skip to main content
SpringerLink
Log in

Ibrutinib

  • Chapter
  • First Online:
Book cover Small Molecules in Hematology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 212))

Abstract

Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton’s tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency. Ibrutinib is currently approved by the FDA and EMA for use in chronic lymphocytic leukaemia in any line of treatment, for treatment of Waldenstrom macroglobulinemia in patients who have received previous treatments or are not suitable to receive immunochemotherapy as well as for second line treatment of mantle cell lymphoma and for patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy. In addition, there is emerging clinical data on its efficacy in ABC subtype diffuse large B-cell lymphoma, multiple myeloma and primary central nervous system lymphoma. Ibrutinib has opened new options for treatment of those patients that have relapsed or have been refractory to more classical modes of treatment. Moreover, Ibrutinib has been shown to be effective in patients that have been known to have little sensitivity to classical immunochemotherapy. Having a favourable risk profile, the substance is, unlike conventional immunochemotherapy, also suitable for the less physical fit patients. Cases of primary and secondary resistance to Ibrutinib have emerged and there is an ongoing effort to identify their mechanism and develop strategies to overcome them. Beyond its direct effects on survival and apoptosis of malignant B-cells, there is increasing evidence that Ibrutinib is able to modulate the tumour microenvironment to overcome mechanisms of immune evasion. This has sparked interest in use of the substance beyond lymphoid malignancy. This chapter discusses structure, mechanism of action and toxicities of Ibrutinib and also presents important preclinical and clinical data as well as mechanisms of Ibrutinib resistance. Combination strategies with immunotherapeutic strategies such as immune checkpoint blockade and CAR T-cell therapy may be synergistic and are currently under investigation.

Disclosure: The authors have nothing to disclose.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31

    Google Scholar 

  • Ahn IE, Underbayev C, Albitar A, Herman SEM, Tian X, Maric I, Arthur DC, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Nierman P, Lotter J, Xi L, Raffeld M, Farooqui M, Albitar M, Wiestner A (2017) Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129(11):1469–1479

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Arthurs B, Wunderle K, Hsu M, Kim S (2017) Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep 21:27–29

    PubMed  PubMed Central  Google Scholar 

  • Asnani A, Manning A, Mansour M, Ruskin J, Hochberg EP, Ptaszek LM (2017) Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-Oncology 3(1):2

    Article  PubMed  PubMed Central  Google Scholar 

  • Barbosa CC, DeAngelis LM, Grommes C (2017) Ibrutinib associated infections: a retrospective study. J Clin Oncol 35(15_suppl):e19020–e19020

    Google Scholar 

  • Barr P, Robak T, Owen CJ, Tedeschi A, Bairey O, Bartlett NL, Burger J, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James DF, Kipps TJ, Ghia P (2016) Updated efficacy and safety from the phase 3 resonate-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. Blood 128(22):234

    Google Scholar 

  • Barrientos JC, Meyer N, Song X, Rai KR (2015) Characterization of atrial fibrillation and bleeding risk factors in patients with chronic lymphocytic leukemia (cll): a population-based retrospective cohort study of administrative medical claims data in the United States (US). Blood 126(23):3301

    Google Scholar 

  • Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98(10):946–952

    Article  PubMed  CAS  Google Scholar 

  • Böttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, Fink AM, Bühler A, Zenz T, Wenger MK, Mendila M, Wendtner C-M, Eichhorst BF, Döhner H, Hallek MJ, Kneba M (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30(9):980–988

    Article  PubMed  Google Scholar 

  • Broides A, Yang W, Conley ME (2006) Genotype/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol 118(2–3):195–200

    Article  PubMed  CAS  Google Scholar 

  • Brown JR, Hillmen P, O’Brien S, Barrientos JC, Reddy N, Coutre S, Tam C, Mulligan S, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel J, Burger JA, Chung D, Lin J, Gau L, Chang B, McGreivy J, James DF, Byrd JC (2014) Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 resonate trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood 124(21):3331

    Google Scholar 

  • Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O’Brien S (2015) The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 125(19):2915–2922

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bruton OC (1952) Agammaglobulinemia. Pediatrics 9(6):722–728

    PubMed  CAS  Google Scholar 

  • Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O’Brien S (2014) Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090–1099

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O’Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425–2437

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Cin PD, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O’Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ (2016) Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat commun 7:11589

    Google Scholar 

  • Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O’Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N (2017) Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2(2):e89904

    Article  PubMed  PubMed Central  Google Scholar 

  • Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O’Brien S (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32–42

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213–223

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O’Brien S (2015) Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125(16):2497–2506

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP (2015) CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)-directed survival signalling in Waldenstrom macroglobulinaemia cells. Br J Haematol 168(5):701–707

    Article  PubMed  CAS  Google Scholar 

  • Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy M-S, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M (2016) Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17(2):200–211

    Article  PubMed  CAS  Google Scholar 

  • Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ (2011) The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 13(4):R115

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Chen J, Kinoshita T, Sukbuntherng J, Chang BY, Elias L (2016a) Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth. Mol Cancer Ther 15(12):2835–2844

    Article  PubMed  CAS  Google Scholar 

  • Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, Burger JA, Rai KR, Chiorazzi N (2016b) BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30(4):833–843

    Article  PubMed  CAS  Google Scholar 

  • Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804–815

    Article  PubMed  CAS  Google Scholar 

  • Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S (2014) Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 4(9):1022–1035

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S (2013) The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 161(1):43–56

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Davids MS, Kim HT, Brander DM, Bsat J, Savell A, Francoeur K, Hellman J, Jacobson CA, Hochberg E, Takvorian R, Abramson JS, Fisher DC, Brown JR (2016) Initial results of a multicenter, phase II study of ibrutinib plus fcr (iFCR) as frontline therapy for younger CLL patients. Blood 128(22):3243

    Google Scholar 

  • Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88–92

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW, Pals ST, Spaargaren M (2007) Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26(1):93–104

    Article  PubMed  CAS  Google Scholar 

  • de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, de Vries R, Jiao JJ, Snoeys J, Mannaert E (2015a) Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect 3(4):e00156

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • de Jong J, Sukbuntherng J, Skee D, Murphy J, O’Brien S, Byrd JC, James D, Hellemans P, Loury DJ, Jiao J, Chauhan V, Mannaert E (2015b) The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol 75(5):907–916

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • de Jong J, Hellemans P, Jiao J, Sukbuntherng J, Ouellet D (2016) An open-label, sequential-design drug interaction study of the effects of omeprazole on the pharmacokinetics of ibrutinib in healthy adults. Blood 128(22):1588

    Google Scholar 

  • de Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor—and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590–2594

    Article  PubMed  CAS  Google Scholar 

  • de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M (2016) Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. Clin Pharmacol Ther 100(5):548–557

    Article  PubMed  CAS  Google Scholar 

  • Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gribling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, Currie KS (2011) Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 7(1):41–50

    Article  PubMed  CAS  Google Scholar 

  • Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, Fernández de Larrea C, Castillo JJ, Granell M, Kyrtsonis M-C, Leblond V, Symeonidis A, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C (2015) Ibrutinib therapy in rituximab-refractory patients with Waldenström’s macroglobulinemia: initial results from an international, multicenter, open-label phase 3 substudy (iNNOVATE). Blood 126(23):2745

    Google Scholar 

  • Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910–1916

    Article  PubMed  Google Scholar 

  • Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387(10020):770–778

    Article  PubMed  CAS  Google Scholar 

  • Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC (2013a) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122(15):2539–2549

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N (2013b) Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood 122(19):3308–3316

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Duong MN, Matera EL, Mathe D, Evesque A, Valsesia-Wittmann S, Clemenceau B, Dumontet C (2015) Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. MAbs 7(1):192–198

    Article  PubMed  CAS  Google Scholar 

  • Falchi L, Baron JM, Orlikowski CA, Ferrajoli A (2016) BCR signaling inhibitors: an overview of toxicities associated with ibrutinib and idelalisib in patients with chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis 8(1):e2016011

    Article  PubMed  PubMed Central  Google Scholar 

  • Farooqui M, Valdez J, Soto S, Bray A, Tian X, Wiestner A (2015a) Atrial fibrillation in CLL/SLL patients on ibrutinib. Blood 126(23):2933

    Google Scholar 

  • Farooqui M, Valdez J, Soto S, Stetler-Stevenson M, Yuan CM, Thomas F, Tian X, Maric I, Wiestner A (2015b) Single agent ibrutinib in CLL/SLL patients with and without deletion 17p. Blood 126(23):2937

    Google Scholar 

  • Farooqui MZH, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SEM, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A (2015c) Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol 16(2):169–176

    Article  PubMed  CAS  Google Scholar 

  • Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer K-A, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner C-M, Döhner H, Stilgenbauer S, Hallek M (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127(2):208–215

    Article  PubMed  CAS  Google Scholar 

  • Gashonia LM, Carver JR, O’Quinn R, Clasen S, Hughes ME, Schuster SJ, Isaac K, Kennard K, Svoboda J, Daniel C, Tsai DE, Fanning MJ, Nasta S, Landsburg DJ, Nabhan C, Mato AR (2017) Persistence of ibrutinib-associated hypertension in CLL pts treated in a real-world experience. J Clin Oncol 35(15_suppl):7525–7525

    Google Scholar 

  • Gill S, Frey NV, Hexner EO, Lacey SF, Melenhorst JJ, Byrd JC, Metzger S, Marcus T, Gladney W, Marcucci K, Hwang W-T, June CH, Porter DL (2017) CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. J Clin Oncol 35(15_suppl):7509–7509

    Google Scholar 

  • Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy M-S, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer K-A, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110

    Article  PubMed  CAS  Google Scholar 

  • Grabinski N, Ewald F (2014) Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs 32(6):1096–1104

    Article  PubMed  CAS  Google Scholar 

  • Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK (2017) Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov 7(9):1018–1029

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM (2016) Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov 6(3):270–285

    Article  PubMed  CAS  Google Scholar 

  • Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, Wang YL (2016a) Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget 7(4):4598–4610

    Article  PubMed  Google Scholar 

  • Guo H, Huang S, Liu Y, Li CJ, Wang J, Zhang V, Ahmed M, Lam LT, Zhang H, Nomie K, Zhang L, Wang M (2016b) Genetic and molecular characterization of ibrutinib-resistant mantle cell lymphoma: designing innovative therapeutic strategies. Blood 128(22):1838

    Google Scholar 

  • Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12):5446–5456

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164–1174

    Google Scholar 

  • Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14(4):219–232

    Article  PubMed  CAS  Google Scholar 

  • Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23):6287–6296

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Herman SE, Mustafa RZ, Jones J, Wong DH, Farooqui M, Wiestner A (2015) Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res 21(20):4642–4651

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C, Mayer J (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25(35):5616–5623

    Article  PubMed  CAS  Google Scholar 

  • Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107(29):13075–13080

    Article  PubMed  PubMed Central  Google Scholar 

  • Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West J-S, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC (2015) Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood 126(7):842–850

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O’Brien S (2015) Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 125(13):2062–2067

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Jerkeman M, Hutchings M, Räty R, Wader KF, Laurell A, Kuitunen H, Toldbod H, Pedersen LB, Eskelund CW, Grønbæk K, Niemann CU, Geisler CH, Kolstad A (2016) Ibrutinib-lenalidomide-rituximab in patients with relapsed/refractory mantle cell lymphoma: first results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial. Blood 128(22):148

    Google Scholar 

  • Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS (2015) Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 29(4):783–787

    Article  PubMed  CAS  Google Scholar 

  • Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC (2014) Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity. Blood 123(12):1957–1960

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kokabee L, Wang X, Sevinsky CJ, Wang WL, Cheu L, Chittur SV, Karimipoor M, Tenniswood M, Conklin DS (2015) Bruton’s tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther 16(11):1604–1615

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K (2017) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia

    Google Scholar 

  • Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal D (2016) The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood

    Google Scholar 

  • Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Sie P, Ysebaert L, Payrastre B (2014) Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 124(26):3991–3995

    Article  PubMed  CAS  Google Scholar 

  • Ma J, Lu P, Guo A, Cheng S, Zong H, Martin P, Coleman M, Wang YL (2014) Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol 166(6):849–861

    Article  PubMed  CAS  Google Scholar 

  • Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA (2015a) A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-hodgkin lymphoma. Blood 125(2):242–248

    Article  PubMed  CAS  Google Scholar 

  • Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA (2015b) Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1(1):80–87

    Article  PubMed  PubMed Central  Google Scholar 

  • Masso-Valles D, Jauset T, Serrano E, Sodir NM, Pedersen K, Affara NI, Whitfield JR, Beaulieu ME, Evan GI, Elias L, Arribas J, Soucek L (2015) Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Cancer Res 75(8):1675–1681

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA, Mollica JP, Zhang L, Zhang Y, Shioi T, Buerger A, Izumo S, Jay PY, Jennings GL (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 104(2):612–617

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS (2014) Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 124(25):3829–3830

    Article  PubMed  CAS  Google Scholar 

  • McNally GA, Long JM, Brophy LR, Badillo MR (2015) Ibrutinib: implications for use in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. J Adv Pract Oncol 6(5):420–431

    PubMed  PubMed Central  Google Scholar 

  • Minden MD-V, Übelhart R, Schneider D, Wossning T, Bach MP, Buchner M, Hofmann D, Surova E, Follo M, Köhler F, Wardemann H, Zirlik K, Veelken H, Jumaa H (2012) Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 489:309

    Article  CAS  Google Scholar 

  • Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, Christensson B, Berglof A, Vihinen M, Nore BF, Smith CI (2009) Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 228(1):58–73

    Article  PubMed  CAS  Google Scholar 

  • Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, Amin HM, Wang M, Marcucci G, Weisenburger DD, Rosen ST, Pham LV, Ngo VN (2016) CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget 7(45):73558–73572

    Article  PubMed  PubMed Central  Google Scholar 

  • Murray MY, Zaitseva L, Auger MJ, Craig JI, MacEwan DJ, Rushworth SA, Bowles KM (2015) Ibrutinib inhibits BTK-driven NF-kappaB p65 activity to overcome bortezomib-resistance in multiple myeloma. Cell Cycle 14(14):2367–2375

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R (2017) Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 129(16):2224–2232

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • O’Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15

    Google Scholar 

  • O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Osterborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S (2016a) Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 17(10):1409–1418

    Article  PubMed  CAS  Google Scholar 

  • O’Brien SM, Furman RR, Coutre SE, Flinn IW, Burger J, Blum K, Sharman J, Wierda WG, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC (2016b) Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. Blood 128(22):233

    Google Scholar 

  • Oda A, Ikeda Y, Ochs HD, Druker BJ, Ozaki K, Handa M, Ariga T, Sakiyama Y, Witte ON, Wahl MI (2000) Rapid tyrosine phosphorylation and activation of Bruton’s tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood 95(5):1663–1670

    PubMed  CAS  Google Scholar 

  • Okamoto K, Proia LA, Demarais PL (2016) Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib. Case Rep Infect Dis 2016:4642831

    PubMed  PubMed Central  Google Scholar 

  • Ortolano S, Hwang IY, Han SB, Kehrl JH (2006) Roles for phosphoinositide 3-kinases, Bruton’s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol 36(5):1285–1295

    Article  PubMed  CAS  Google Scholar 

  • Pan Z, Scheerens H, Li S-J, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KCK, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT (2007) Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2(1):58–61

    Article  PubMed  CAS  Google Scholar 

  • Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M (2016) Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood 128(12):1609–1613

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ping L, Ding N, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y, Zhu J (2017) The Bruton’s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Oncotarget 8(24):39218–39229

    Article  PubMed  PubMed Central  Google Scholar 

  • Ponader S, Chen S-S, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O’Brien S, Chiorazzi N, Burger JA (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182–1189

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dorken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F (2014) Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med 20(1):87–92

    Article  PubMed  CAS  Google Scholar 

  • Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ (2013) BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 25(1):106–112

    Article  PubMed  CAS  Google Scholar 

  • Sagiv-Barfi I, Kohrt HEK, Czerwinski DK, Ng PP, Chang BY, Levy R (2015) Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci 112(9):E966–E972

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Satterthwaite AB, Witte ON (2000) The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 175:120–127

    Article  PubMed  CAS  Google Scholar 

  • Scharenberg AM, Humphries LA, Rawlings DJ (2007) Calcium signalling and cell-fate choice in B cells. Nat Rev Immunol 7(10):778–789

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G (2015) Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos 43(2):289–297

    Article  PubMed  CAS  Google Scholar 

  • Schwamb J, Feldhaus V, Baumann M, Patz M, Brodesser S, Brinker R, Claasen J, Pallasch CP, Hallek M, Wendtner C-M, Frenzel LP (2012) B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood 120(19):3978–3985

    Article  PubMed  CAS  Google Scholar 

  • Seda V, Mraz M (2015) B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 94(3):193–205

    Article  PubMed  CAS  Google Scholar 

  • Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, Kwak LW, Samaniego F (2014) FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia 28(12):2376–2387

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Shao J, Markowitz JS, Bei D, An G (2014) Enzyme-transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci 103(12):3810–3833

    Google Scholar 

  • Sideras P, Muller S, Shiels H, Jin H, Khan WN, Nilsson L, Parkinson E, Thomas JD, Branden L, Larsson I et al (1994) Genomic organization of mouse and human Bruton’s agammaglobulinemia tyrosine kinase (Btk) loci. J Immunol 153(12):5607–5617

    PubMed  CAS  Google Scholar 

  • Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118(16):4313–4320

    Article  PubMed  CAS  Google Scholar 

  • Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, Harrington B, Old M, Reiff S, Mace T, Tridandapani S, Muthusamy N, Caligiuri MA, Byrd JC, Carson WE 3rd (2016) Myeloid-derived suppressor cells express Bruton’s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res 76(8):2125–2136

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tai Y-T, Chang BY, Kong S-Y, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao J-J, Cagnetta A, Cea M, Sellitto MA, Zhong MY, Wang Q, Acharya C, Carrasco DR, Buggy JJ, Elias L, Treon SP, Matsui W, Richardson P, Munshi NC, Anderson KC (2012) Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120(9):1877–1887

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O’Brien S, Davis RE, Burger JA (2015) CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726–735

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Thompson PA, Levy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F (2016) Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol 175(3):462–466

    Article  PubMed  CAS  Google Scholar 

  • Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH (2015) Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med 372(15):1430–1440

    Article  PubMed  CAS  Google Scholar 

  • Vij R, Huff CA, Bensinger WI, Siegel DS, Jagannath S, Berdeja J, Lendvai N, Lebovic D, Anderson LD, Costello CL, Stockerl-Goldstein KE, Laubach JP, Elias L, Clow F, Fardis M, Graef T, Bilotti E, Richardson PG (2014) Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed/refractory multiple myeloma (mm): preliminary phase 2 results. Blood 124(21):31

    Google Scholar 

  • Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016) Proposed algorithm for managing ibrutinib-related atrial fibrillation. Oncology (Williston Park) 30(11):970–974, 980-971, C973

    Google Scholar 

  • Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507–516

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S (2015) Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 126(6):739–745

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wang M, Lee HJ, Thirumurthi S, Chuang HH, Hagemeister FB, Westin JR, Fayad LE, Samaniego F, Turturro F, Chen W, Oriabure O, Huang SY, Li S, Zhang L, Badillo M, Hartig KH, Ahmed M, Nomie K, Lam LT, Addison AA, Romaguera JE (2016a) Chemotherapy-free induction with ibrutinib-rituximab followed by shortened cycles of chemo-immunotherapy consolidation in young, newly diagnosed mantle cell lymphoma patients: a phase II clinical trial. Blood 128(22):147

    Google Scholar 

  • Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L (2016b) Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48–56

    Article  PubMed  CAS  Google Scholar 

  • Wang J, Liu X, Hong Y, Wang S, Chen P, Gu A, Guo X, Zhao P (2017) Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. J Exp Clin Cancer Res 36(1):96

    Article  PubMed  PubMed Central  Google Scholar 

  • Wei L, Su YK, Lin CM, Chao TY, Huang SP, Huynh TT, Jan HJ, Whang-Peng J, Chiou JF, Wu AT, Hsiao M (2016) Preclinical investigation of ibrutinib, a Bruton’s kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget 7(43):69961–69975

    PubMed  PubMed Central  Google Scholar 

  • Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih C-J, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922–926

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O’Brien S, Burger JA (2014) Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123(26):4132–4135

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120(6):1175–1184

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH-H, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC (2014a) Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 370(24):2286–2294

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O’Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC (2014b) Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123(12):1810–1817

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP (2017) Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood 129(18):2519–2525

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6):723–737

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y (2014) Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 15(9):1019–1026

    Article  PubMed  CAS  Google Scholar 

  • Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM (2015) B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol 52(2):77–85

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zucha MA, Wu AT, Lee WH, Wang LS, Lin WW, Yuan CC, Yeh CT (2015) Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Oncotarget 6(15):13255–13268

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine and Dentistry, Queen Mary University of London, London, UK

    Andriani Charalambous

  2. Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK

    Mark-Alexander Schwarzbich

  3. Department of Haematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany

    Mark-Alexander Schwarzbich & Mathias Witzens-Harig

Authors
  1. Andriani Charalambous
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark-Alexander Schwarzbich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mathias Witzens-Harig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark-Alexander Schwarzbich .

Editor information

Editors and Affiliations

  1. MOLIT Institute, Cancer Center Heilbronn-Franken, SLK-Clinics, Heilbronn, Baden-Württemberg, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Charalambous, A., Schwarzbich, MA., Witzens-Harig, M. (2018). Ibrutinib. In: Martens, U. (eds) Small Molecules in Hematology. Recent Results in Cancer Research, vol 212. Springer, Cham. https://doi.org/10.1007/978-3-319-91439-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-91439-8_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-91438-1

  • Online ISBN: 978-3-319-91439-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation